April 18, 2026 — RNews

#immunotherapy — Saturday, April 18, 2026 (1 items)

hot top new

← prev day next day →

0

Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study. (linkinghub.elsevier.com)

Colombo N … Wu X The Lancet 2026-04-18

#amr #clinical trial #immunotherapy #chemotherapy #ovarian cancer